Skip to main content
SpringerLink
Log in

Monitoring the Spread of SARS-CoV-2 Gene Variants in Sverdlovsk and Chelyabinsk Oblasts and Perm Krai

  • EXPERIMENTAL PAPERS
  • Published:
Molecular Genetics, Microbiology and Virology Aims and scope Submit manuscript

Abstract

A genomic diversity study of SARS-CoV-2 was conducted in the context of lifting the coronavirus restrictions and reopening Russia’s national borders. SARS-CoV-2 genovariants in Sverdlovsk and Chelyabinsk oblasts and Perm krai were identified. A total of 1127 nasopharyngeal smears from patients with a new coronavirus infection treated in Sverdlovsk and Chelyabinsk oblasts and Perm krai were studied by Sanger sequencing. The paper presents the dynamics of new coronavirus strains and its several mutations for the period from May to December 2022 using descriptive statistics. The study period was notable for Omicron predominance (~97%) with a greater number of amino acid mutations compared with that for the Delta and Alpha variants. The Omicron BA.2 subvariant prevailed during the study period from May to September and from October to December 2022, then BA.2 was displaced by BA.4/BA.5 subvariants. Molecular similarity analysis for assessment of SARS-CoV-2 showed the presence of atypical mutations at positions E484K, G485R, and R408I in some samples, as well as an increase in the number of mutations in variants, especially in the receptor-binding domain RBD. According to the literature, amino acid substitutions led to an S protein conformational alteration which, in turn, increased the affinity of RBD binding to ACE2 and resulted in a milder disease and higher contagiousness compared with earlier SARS-CoV-2 variants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.

REFERENCES

  1. Plante, J.A., Mitchell, B.M., Plante, K.S., Debbink, K., Weaver, S.C., and Menachery, V.D., The variant gambit: COVID-19’s next move, Cell Host Microbe, 2021, vol. 29, no. 4, pp. 508–515. https://doi.org/10.1016/j.chom.2021.02.020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Fernandes, Q., Inchakalody, V.P., Merhi, M., Mestiri, S., Taib, N., Moustafa Abo El-Ella, D., et al., Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines, Ann. Med., 2022, vol. 54, no. 1, pp. 524–540. https://doi.org/10.1080/07853890.2022.2031274

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Aleem, A., Akbar Samad, A.B., and Slenker, A.K., Emerging Variants of SARS-CoV-2 and Novel Therapeutics against Coronavirus (COVID-19), Treasure Island, FL: StatPearls Publ., 2022. PMID 34033342.

  4. Liu, H., Wei, P., Kappler, J.W., Marrack, P., and Zhang, G., SARS-CoV-2 variants of concern and variants of interest receptor binding domain mutations and virus infectivity, Front. Immunol., 2022, vol. 13, p. 825256. PMID 35154144; PMCID PMC8828474. https://doi.org/10.3389/fimmu.2022.825256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Choi, J.Y. and Smith, D.M., SARS-CoV-2 variants of concern, Yonsei Med. J., 2021, vol. 62, no. 11, pp. 961–968. PMID 34672129; PMCID PMC8542474. https://doi.org/10.3349/ymj.2021.62.11.961

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Tiecco, G., Storti, S., Degli Antoni, M., Focà, E., Castelli, F., and Quiros-Roldan, E., Omicron genetic and clinical peculiarities that may overturn SARS-CoV-2 pandemic: A literature review, Int. J. Mol. Sci., 2022, vol. 23, no. 4, p. 1987. PMID 35216104; PMCID PMC8876558. https://doi.org/10.3390/ijms23041987

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Le, T.T.B., Vasanthakumaran, T., Thi Hien, H.N., Hung, I.C., Luu, M.N., Khan, Z.A., et al., SARS-CoV-2 Omicron and its current known unknowns: A narrative review, Rev. Med. Virol., 2023, vol. 33, no. 1, p. e2398. PMID 36150052; PMCID PMC9538895. https://doi.org/10.1002/rmv.2398

    Article  CAS  PubMed  Google Scholar 

  8. Greaney, A.J., Loes, A.N., Crawford, K.H.D., Starr, T.N., Malone, K.D., Chu, H.Y., and Bloom, J.D., Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies, Cell Host Microbe, 2021, vol. 29, no. 3, pp. 463–476.e6. PMID 33592168; PMCID PMC7869748. https://doi.org/10.1016/j.chom.2021.02.003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ridgway, H., Ntallis, C., Chasapis, C.T., Kelaidonis, K., Matsoukas, M.T., Plotas, P., et al., Molecular epidemiology of SARS-CoV-2: The dominant role of arginine in mutations and infectivity, Viruses, 2023, vol. 15, no. 2, p. 309. PMID 36851526; PMCID PMC9963001. https://doi.org/10.3390/v15020309

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wang, Q., Guo, Y., Iketani, S., Nair, M.S., Li, Z., Mohri, H., et al., Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5, Nature, 2022, vol. 608, no. 7923, pp. 603–608. PMID 35790190; PMCID PMC9385487. https://doi.org/10.1038/s41586-022-05053-w

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cox, M., Peacock, T.P., Harvey, W.T., Hughes, J., Wright, D.W., COVID-19 Genomics UK (COG-UK) Consortium, Willett, B.J., Thomson, E., Gupta, R.K., Peacock, S.J., Robertson, D.L., and Carabelli, A.M., SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies, Nat. Rev. Microbiol., 2023, vol. 21, no. 2, pp. 112–124. PMID 36307535; PMCID PMC9616429. https://doi.org/10.1038/s41579-022-00809-7

    Article  CAS  PubMed  Google Scholar 

  12. Aksamentov, I., Roemer, C., Hodcroft, E.B., and Neher, R.A., Nextclade: clade assignment, mutation calling and quality control for viral genomes, J. Open Source Software, 2021, vol. 6, no. 67, p. 3773. https://doi.org/10.21105/joss.03773

    Article  ADS  Google Scholar 

  13. World Health Organization. COVID-19 Weekly Epidemiological Update, Edition 96, June 15, 2022.

  14. World Health Organization. COVID-19 Weekly Epidemiological Update, Edition 121, December 07, 2022.

  15. Fiolet, T., Kherabi, Y., MacDonald, C.J., Ghosn, J., and Peiffer-Smadja, N., Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review, Clin. Microbiol. Infect., 2022, vol. 28, no. 2, pp. 202–221. PMID 34715347; PMCID PMC8548286. https://doi.org/10.1016/j.cmi.2021.10.005

    Article  CAS  PubMed  Google Scholar 

  16. Kumar, V., Singh, J., Hasnain, S.E., and Sundar, D., Possible link between higher transmissibility of alpha, kappa and delta variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity, Int. J. Mol. Sci., 2021, vol. 22, no. 17, p. 9131. PMID 34502041; PMCID PMC8431609. https://doi.org/10.3390/ijms22179131

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Khan, K., Karim, F., Ganga, Y., Bernstein, M., Jule, Z., Reedoy, K., Cele, S., Lustig, G., Amoako, D., Wolter, N., Samsunder, N., Sivro, A., San, J.E., Giandhari, J., Tegally, H., Pillay, S., Naidoo, Y., Mazibuko, M., Miya, Y., Ngcobo, N., Manickchund, N., Magula, N., Karim, Q.A., von Gottberg, A., Abdool Karim, S.S., Hanekom, W., Gosnell, B.I., COMMIT-KZN Team, Lessells, R.J., de Oliveira, T., Moosa, M.S., and Sigal, A., Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection, Nat. Commun., 2022, vol. 13, no. 1, p. 4686. Erratum in Nat. Commun., 2022, vol. 13, no. 1, p. 6057. PMID 35948557; PMCID PMC9364294. https://doi.org/10.1038/s41467-022-32396-9

    Article  CAS  Google Scholar 

  18. Ai, J., Wang, X., He, X., Zhao, X., Zhang, Y., Jiang, Y., Li, M., Cui, Y., Chen, Y., Qiao, R., Li, L., Yang, L., Li, Y., Hu, Z., Zhang, W., and Wang, P., Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages, Cell Host Microbe, 2022, vol. 30, no. 8, pp. 1077–1083.e4. PMID 35594867; PMCID PMC9080084. https://doi.org/10.1016/j.chom.2022.05.001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Shaheen, N., Mohamed, A., Attalla, A., Diab, R.A., Swed, S., Nashwan, A.J., Rababah, A.A., Hefnawy, M.T., Soliman, Y., Abdelwahab, O.A., Desouki, M.T., Kha-ity, A., Shaheen, A., Ramadan, A., and Meshref, M., Could the new BA.2.75 sub-variant cause the emergence of a global epidemic of COVID-19? A scoping review, Infect. Drug Resist., 2022, vol. 15, pp. 6317–6330. PMID 36345537; PMCID PMC9635999. https://doi.org/10.2147/IDR.S387551

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was supported by a grant within the framework of the federal project “Sanitary Shield—Safety for Health (Prevention, Detection, Response),” as well as within the framework of the research work “Integrated Approach to the Study of Epidemiological and Molecular Genetic Characteristics of Influenza and Acute Respiratory Viral Infection in Severe Clinical Forms During Mass Vaccination,” reg. no. 121041500044-2.

Author information

Authors and Affiliations

  1. Federal Research Institute of Viral Infections “Virome”, Yekaterinburg, Russia

    A. E. Chernysheva, I. A. Korotkova, E. V. Bolgarova, A. Yu. Markaryan & A. V. Semenov

  2. Ural State Medical University, 620014, Yekaterinburg, Russia

    A. V. Semenov

Authors
  1. A. E. Chernysheva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. A. Korotkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. V. Bolgarova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Yu. Markaryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. V. Semenov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. E. Chernysheva.

Ethics declarations

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was approved by the Ethics Committee of the State Research Center of Virology and Biotechnology “Vector” of the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), Protocol No. 4 dated September 8, 2022. All participants were informed about the goal, methodology, and possible risks of the study. Informed consent was signed by all individual participants involved in the study.

CONFLICT OF INTEREST

The authors of this work declare that they have no conflicts of interest.

Additional information

Translated by M. Novikova

Publisher’s Note.

Allerton Press remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chernysheva, A.E., Korotkova, I.A., Bolgarova, E.V. et al. Monitoring the Spread of SARS-CoV-2 Gene Variants in Sverdlovsk and Chelyabinsk Oblasts and Perm Krai. Mol. Genet. Microbiol. Virol. 38, 226–232 (2023). https://doi.org/10.3103/S0891416823040031

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3103/S0891416823040031

Keywords:

Search

Navigation